Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality9/10

Vericel lifts 2026 guidance on MACI growth; announces $200M buyback

Jul 30, 2026, 7:59 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Solid revenue growth, a debt-free balance sheet, and a large buyback signal meaningful upside near-term; raised guidance confirms momentum, likely supporting a multiple expansion.

AI summary

What happened, with direct paths to the underlying reporting

Vericel delivered a strong Q2 2026, with total revenue up 22% and MACI growth at 23%. The firm authorized a $200 million buyback and raised full-year guidance to $330-340 million, reflecting solid MACI and Burn Care momentum and robust cash flow on a debt-free balance sheet. Regulatory upside includes UK MACI Arthro submission, adding optionality to the growth story.

Q2 2026 revenue up 22% to $77.5M; MACI up 23% to $65.5M.
H1 2026 revenue up 26% to $145.9M; Burn Care up 49% to $24.0M.
Net income $2.2M; gross margin 73%; non-GAAP EBITDA margin 19%.
Cash and investments about $227M; no debt; $200M share repurchase authorized.
2026 guidance raised: revenue $330-340M; MACI $284-290M; UK MACI Arthro submission.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.